Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 24:1:25.
doi: 10.1186/s42466-019-0032-2. eCollection 2019.

Evaluation of a programming algorithm for deep brain stimulation in dystonia used in a double-blind, sham-controlled multicenter study

Frank Steigerwald #  1   2   3 , Anna Dalal Kirsch #  1 , Andrea A Kühn  4 , Andreas Kupsch  5 , Joerg Mueller  6   7 , Wilhelm Eisner  8 , Günther Deuschl  3 , Daniela Falk  9 , Alfons Schnitzler  10 , Inger Marie Skogseid  11 , Juliane Vollmer-Haase  12 , Chi W Ip  1 , Volker Tronnier  13 , Jan Vesper  14   15 , Markus Naumann  1   16 , Jens Volkmann  1   3 ; DBS study group for dystonia
Collaborators, Affiliations

Evaluation of a programming algorithm for deep brain stimulation in dystonia used in a double-blind, sham-controlled multicenter study

Frank Steigerwald et al. Neurol Res Pract. .

Abstract

Background: Programming deep brain stimulation in dystonia is difficult because of the delayed benefits and absence of evidence-based guidelines. Therefore, we evaluated the efficacy of a programming algorithm applied in a double-blind, sham-controlled multicenter study of pallidal deep brain stimulation in dystonia.

Methods: A standardized monopolar review to identify the contact with the best acute antidystonic effect was applied in 40 patients, who were then programmed 0.5 V below the adverse effect threshold and maintained on these settings for at least 3 months, if tolerated. If no acute effects were observed, contact selection was based on adverse effects or anatomical criteria. Three-year follow-up data was available for 31 patients, and five-year data for 32 patients. The efficacy of the algorithm was based on changes in motor scores, adverse events, and the need for reprogramming.

Results: The mean (±standard deviation) dystonia motor score decreased by 73 ± 24% at 3 years and 63 ± 38% at 5 years for contacts that exhibited acute improvement of dystonia (n = 17) during the monopolar review. Contacts without acute benefit improved by 58 ± 30% at 3 years (n = 63) and 53 ± 31% at 5 years (n = 59). Interestingly, acute worsening or induction of dystonia/dyskinesia (n = 9) correlated significantly with improvement after 3 years, but not 5 years.

Conclusions: Monopolar review helped to detect the best therapeutic contact in approximately 30% of patients exhibiting acute modulation of dystonic symptoms. Acute improvement, as well as worsening of dystonia, predicted a good long-term outcome, while induction of phosphenes did not correlate with outcome.

Trial registration: ClinicalTrials.gov NCT00142259.

Keywords: Deep brain stimulation; Dystonia; Long-term outcome; Pallidum; Programming algorithm.

PubMed Disclaimer

Conflict of interest statement

Competing interestsAll authors report no potential conflict of interest regarding this manuscript. Over the last 12 months FS report grants and personal fees from Boston Scientific, a research grant from Medtronic and personal fees from Abbott for educational trainings, JV received grants from Medtronic and Boston Scientific as well as personal fees from Medtronic, Abbott, Boston Scientifc, UCB, Merz, Allergan, TEVA, Novartis, Abbvie, Grünenthal and Newronika. GD has received lecture fees from Boston Scientific and has been serving as a consultant for Boston Scientific. He received royalties from Thieme publishers. He is a government employee and receives through his institution funding for his research from the German Research Council, the German Ministery of Education and Research and Medtronic. JVe reports grants and consultancies from Abbott and Boston Scientific over the last 12 months. CWI reports honoraria from Allergan Inc., Merz Pharmaceutical and Ipsen Pharm and travel grants from Desitin over the last 12 months. AS has been serving as a consultant for Medtronic Inc., Boston Scientific, St. Jude Medical, Grünenthal and has received lecture fees from Abbvie, Boston Scientific, St. Jude Medical, Medtronic Inc., UCB, MEDA Pharma, Teva Pharma, and GlaxoSmithKline. AS is a government employee and receives through his institution funding for his research from the German Research Council, the German Ministery of Education and Health, and the Gossweiler Foundation. JM reports honoraria from Merz Pharmaceutical over the last 12 months. AKü reports consultancies for Boston Scientific and Abbott. AKu reports honoraria from Zamson and Merz DF, JVH, MN and WE report no financial disclosure over the last 12 months.

Figures

Fig. 1
Fig. 1
Flow chart describing the basic procedure of the original study protocol for configuring the device during the monopolar review session. Numbers depicted on the right give the percentage of electrode contacts chosen using this criterion at the beginning of our study
Fig. 2
Fig. 2
Reduction in the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) motor score after 3 years, depending on choice criteria for contact selection (Wilcoxon multiple
See this image and copyright information in PMC

References

    1. Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. European Journal of Neurology. 2011;18(1):5–18. doi: 10.1111/j.1468-1331.2010.03042.x. - DOI - PubMed
    1. Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: Evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. European Journal of Neurology. 2004;11(6):361–370. doi: 10.1111/j.1468-1331.2004.00845.x. - DOI - PubMed
    1. Benabid AL, Koudsie A, Benazzouz A, Vercueil L, Fraix V, Chabardes S, et al. Deep brain stimulation of the corpus luysi (subthalamic nucleus) and other targets in Parkinson’s disease. Extension to new indications such as dystonia and epilepsy. Journal of Neurology. 2001;248(Suppl 3):III37–III47. doi: 10.1007/PL00007825. - DOI - PubMed
    1. Cheung T, Noecker AM, Alterman RL, McIntyre CC, Tagliati M. Defining a therapeutic target for pallidal deep brain stimulation for dystonia. Annals of Neurology. 2014;76(1):22–30. doi: 10.1002/ana.24187. - DOI - PubMed
    1. Horn SC, Comella CL. Treatment of dystonia. In: Jankovic JT, editor. Parkinson’s disease and movement disorders. Philadelphia: Lippincott Williams & Wilkins; 2002. pp. 358–364.

Associated data

LinkOut - more resources